National Health Determination under paragraph 98C(1)(b) Amendment 2014 (No. 11) (No. PB 90 of 2014)

Overview

The National Health Determination under paragraph 98C(1)(b) Amendment 2014 (No. 11) (PB 90 of 2014) amends the National Health Act 1953 to update the conditions for payments made by the Commonwealth in respect of pharmaceutical benefits supplied by approved pharmacists and approved medical practitioners. This amendment responds to changes made by the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2014 (No. 11), which took effect on 1 December 2014. The Act, enacted by the Australian Parliament, establishes the Pharmaceutical Benefits Scheme (PBS) to ensure Australians have reliable, timely, and affordable access to a wide range of medicines. The determination process involves consultation with the Pharmaceutical Benefits Advisory Committee (PBAC), an independent body comprising members from various healthcare professions and consumer interests. This legislative instrument ensures the PBS remains aligned with the evolving needs of the community by adding three new drugs and a specific form of an existing drug to the list of subsidised medicines.

Scope and Application

The National Health Determination under paragraph 98C(1)(b) Amendment 2014 (No. 11) pertains to the conditions under which the Commonwealth makes payments for pharmaceutical benefits supplied by approved pharmacists and approved medical practitioners under the National Health Act 1953. This legislation applies to entities and individuals involved in the supply of pharmaceuticals within the Pharmaceutical Benefits Scheme (PBS), ensuring that the Commonwealth's financial contributions to the PBS are made subject to specified conditions. The determination has a national jurisdictional reach, as it is a Commonwealth instrument that impacts the entire Australian population by regulating the supply of pharmaceutical benefits. This Amendment Determination adds specific drugs to Schedule 4 of the Principal Determination, reflecting changes made by the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2014 (No. 11). The amendment, which came into effect on 1 December 2014, includes fluticasone with vilanterol, umeclidinium, umeclidinium with vilanterol, and escitalopram in the form oral solution 20 mg (as oxalate) per mL, 15 mL, to the list of drugs eligible for subsidy under the PBS. The legislation ensures that the conditions for Commonwealth payments are updated to include these new pharmaceuticals, thereby extending the scope of the PBS.

Key Provisions

The main operative sections of this legislative instrument pertain to the National Health Act 1953 (section 98C(1)(b)), which empowers the Minister to determine the conditions under which payments will be made by the Commonwealth for the supply of pharmaceutical benefits by approved pharmacists and approved medical practitioners. This amendment, the National Health Determination under paragraph 98C(1)(b) Amendment 2014 (No. 11), updates the Principal Determination (PB 119 of 2008) to reflect the changes made by the National Health (Listing of Pharmaceutical Benefits) Amendment Instrument 2014 (No. 11), effective from 1 December 2014. Specifically, this amendment adds fluticasone with vilanterol, umeclidinium, and umeclidinium with vilanterol to Schedule 4, and includes escitalopram in the form of an oral solution 20 mg (as oxalate) per mL, 15 mL. This amendment aims to enhance access to these pharmaceutical benefits under the Pharmaceutical Benefits Scheme (PBS). The obligations and requirements imposed by this amendment are primarily directed at ensuring that the revised conditions for payments under the PBS are adhered to by approved pharmacists and approved medical practitioners. These parties must now account for the newly listed drugs in their practice and ensure that they comply with the updated terms of the Pharmaceutical Benefits Determination. The amendment ensures that the revised conditions are transparent and are followed diligently to maintain the integrity of the PBS. The Pharmaceutical Benefits Advisory Committee (PBAC), which has an independent and expert role, provides recommendations to the Minister regarding the suitability of these additions, ensuring that decisions are evidence-based and in line with public health needs. Failure to comply with the updated conditions set out in this amendment could result in penalties or other consequences, although the specific penalties are not detailed in the provided text. Generally, under the National Health Act 1953, non-compliance with the conditions of the PBS could lead to civil or criminal consequences, including fines and potential legal action. The penalties for breaches could vary depending on the nature and severity of the non-compliance. The Act also empowers the Minister to revoke or vary the Principal Determination, ensuring that the PBS remains adaptable to changes in medical needs and public health priorities. This legislative instrument is compatible with human rights as it aims to progressively realise the right to the highest attainable standard of physical and mental health, as recognised in the International Covenant on Economic, Social and Cultural Rights. By ensuring that more pharmaceuticals are available under the PBS, the amendment supports the right of Australians to access necessary medications, thereby advancing the protection of human rights. The involvement of the Pharmaceutical Benefits Advisory Committee ensures that decisions are made with consideration for evidence and public health, further supporting the human rights framework.